INTRODUCTION
Overactive bladder (OAB) is a term used to describe symptoms of urinary frequency, urgency with or without urge incontinence (1) . Because the patients with OAB are often reluctant to seek medical help, the actual incidence is difficult to be assessed. The OAB is generally more common in women than in men and estimated to affect between 50 and 100 million people worldwide (2) . Traditional anticholinergic drugs are the "gold standard" for treating the OAB today. Tremendous advances over the past few years, especially with advanced drug delivery systems, have improved efficacy and decreased side effects when treating OAB. However, most urologists would readily acknowledge that when it comes to treating our patients with OAB, we still have a long way to go in finding drugs that can further improve efficacy and decrease the incidence and severity of side effects (3) . The basic science associated with voiding function is on the way of its development to understand pathophysiology underlying OAB. In this article we try to forecast how urologists will treat the OAB 
Bladder-specific anticholinergics
Pharmacologically defined subtype-selective drugs have been developed. Darifenacin and vamicamide have recently been demonstrated to be selective for the M3 receptor subtype.
Darifenacin, which has 11 times the affinity for M3 that it has for M2 receptors, was similar in potency to atropine in blocking acetylcholine (ACh)-induced contractions of the guinea pig urinary bladder but had one-fifth the affinity of atropine for M3 receptors in the parotid gland (6) . Similarly, in the anesthetized dog, darifenacin was 8.6 times as potent in blocking pelvic nerve-evoked bladder contractions as in suppressing trigeminal nerve-evoked salivation (7) . Thus, darifenacin is a highly promising M3 subtype-affinity agent under investigation for OAB. If the phase 3 studies confirmed the pharmacologic advances, darifenacin would be an attractive agent. 
Antidiuretic hormones
Desmopressin is a synthetic vasopressin analog with strong antidiuretic effects. The drug is commonly used in children with nocturnal enuresis. The use of desmopressin at bedtime for bothersome nocturia is becoming more popular nowadays.
The initial reports in patients with neurogenic bladder dysfunction were encouraging (8) . More recently, desmopressin is being considered for treatment of nocturia associated with benign prostatic hypertrophy (BPH) and OAB. Cautions must be practiced before considering desmopressin in any patient with cardiovascular risk factors, including angina and congestive heart failure. Dilutional hyponatremia can occur very quickly and pose a health risk to these patients. 
Tachykinin antagonists and afferent peptides
Tachykinins released in the bladder can act on: 1) NK-1 receptors in blood vessels to induce plasma extravasation and vasodilation; 2) NK-2 receptors to stimulate the bladder contractions; and 3) NK-2 receptors on primary afferent terminals to increase excitability during bladder filling or during bladder inflammation (18) . Substance P also acts on receptors on urothelial cells to release nitric oxide (NO).
Intrathecal administration of NK-1 antagonists increased bladder capacity in normal conscious rats without changing voiding pressure, whereas NK-2 antagonists were ineffective.
Bladder hyperactivity in rats was also suppressed by intrathecal injection of NK-1 antagonists. Bladder hyperactivity induced by capsaicin was reduced by an NK-2 antagonist (SR 48,965) that did not influence normal voiding (19) . TAK-637, which is a highly specific antagonist for the NK-1 receptor, is also reportedly effective to suppress bladder activity in guinea pigs (20) . The key advantage of tachykinin antagonists is that there is essentially no decrease in detrusor contractility and no increase in residual urine or retention risk. The drug works on the sensory nerves innervating the bladder and not on the bladder itself. Would it not be lovely to have one drug that can help not OAB, irritable symptoms of BPH, and interstitial cystitis and yet causes no dry mouth or risk of urinary retention?
Detrusor specific β3-adrenergic receptor agonists
A fascinating and promising new approach for the treatment of the OAB that the general urology community may not be familiar with is use of β3-adrenergic receptor agonists. Recent studies have demonstrated that the predominant bladder β-adrenergic receptor subtype in humans is the β3-receptor.
Thus, selective activation of β3-adernergic receptors could be useful for treating OAB by directly relaxing human bladder smooth muscle with, we hope, minimal systemic side effects (21).
Advanced drug delivery
Intravesical instillation of oxybutynin has been demonstrated to have efficacy in patients with OAB in whom oral oxybutynin failed, proved subtherapeutic, or was not tolerated. Let's consider an apparent oxybutynin paradox: Why can higher concentrations of oxybutynin be delivered via intravesical instillation, dermal patch, or oral controlled-release technology with less side effects than oral immediate-release oxybutynin?
The key is that dry mouth, due to anticholinergic effects on the salivary gland, is produced to a much greater extent by oxybutynin's metabolite, desethyloxybutynin, than by the parent compound itself. Desethyloxybutynin is produced not only by In patients with idiopathic detrusor instability, numbers of detrusor P2X2 receptors were significantly elevated, whereas those of other P2X receptor subtypes were significantly decreased (23) . There was no detectable purinergic component of nerve-mediated detrusor muscle contractility in normal women without instability. However, there was a significant (approximately 80%) purinergic contractility component in bladder of women with detrusor instability.
In conclusion, the purinergic pathway may be a novel target for the pharmacological treatment of OAB. P2X-receptor acting agents could modulate efferent/afferent activities to treat OAB if receptor subtype-specific agents become available.
Bladder-selective PDE inhibitors
Phosphodiesterase (PDE) is the enzyme that catalyzes the degradation of cyclic adenosine monophosphate (cAMP) to AMP and thus limits the action of cAMP. There are several classes of PDEs that have individual substrate affinities, specific species and tissue distributions, and pharmacologic selectivities (25) . Considerable research is currently under way to try to identify the specific isoform of PDE present in the bladder as opposed to that in the penis. Selective inhibition of bladder PDE would result in both an increase in the basal levels of cAMP (and possibly relaxation of the detrusor) and enhancement of the sensitivity and efficacy of β-adrenergic receptor agonists. Thus, a selective β-adrenergic receptor agonist or a selective PDE inhibitor might prove effective alone or in combination for relaxation of the detrusor.
Star Trek Urology: To Boldly Go Where No
Urologists Have Gone Before
Pharmacogenomic medicine
Through microarray gene chip technology, we can determine a patient's drug metabolism profile, receptor profile, and allergy risk. These factors can be used to screen a list of medications prior to therapy. A urologist will then always be able to choose the best drug for each patient every time without the risk of allergic reaction.
Gene therapy
The bladder is ideally suited for molecular medicine.
Through gene therapy we can replace, supplement, or suppress a protein or cytokine to correct a disease process. I would like to give three examples. 
CONCLUSIONS
The OAB is a rising clinical problem, which provides a considerable challenge for the urologists. We believe that there is great hope for future translational research on voiding dysfunction and urinary incontinence. We believe that the key to the next major advance is to focus on afferent nerve intervention to prevent OAB. Afferent blockade, a revised treatment approach, targets the afferent nerves that control the bladder. Wouldn't it be more desirable to prevent urgency and 
